Division of Quest Diagnostics Inc.
Latest From Celera Corp.
Epigenomics, RainDance, and Brightree name new leadership, and more personnel news from around the industry.
Roche subsidiary hopes recent deals with 23andMe and Human Longevity for whole genome sequencing will help identify targets and biomarkers for Parkinson's disease and other non-cancer conditions. Firm also is taking a personalized medicine approach to development of treatments for pain, macular degeneration and asthma.
The company outbid two rivals to win Pharmacyclics and its fast-growing cancer drug Imbruvica in an expensive acquisition that will cost AbbVie about $21 billion. But the fact that Pharmacyclics shares sales and profits on Imbruvica with J&J may leave some investors questioning the high premium.
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Celera Group
- Celera Genomics Group
- North America
- Parent & Subsidiaries
- Quest Diagnostics Inc.
- Senior Management
Kathy Ordonez, CEO
Alfred Merriweather, SVP, CFO
Stacey Sias, SVP, Bus. Dev. & Strategic Planning
Tom White, PhD, SVP, CSO
- Contact Info
Phone: (510) 749-4200
1401 Harbor Bay Pkwy.
Alameda, CA 94502
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.